{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Drug Slows Progression in Refractory HER2+ Breast Cancer

Activity Steps

Purpose of Activity

To provide information on the results of the HER2CLIMB trial.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Identify the indication for and potential toxicities from tucatinib.
  2. Evaluate results from the HER2CLIMB trial related to progression-free survival and overall survival with the use of tucatinib.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.







Test Code: OT0420
Published: April 2020
Expires: 3/4/2022
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Peter M. Goodwin